000			03225nam a22003257a 4500
001			20241111115741.0
003			OCoLC
005			20241111120329.0
008			241111b |||||||| |||| 00| 0 eng d
020			_a978-0-470-09313-9 (cloth: alk. paper)
040			_cddc
041			_aEnglish
082			_a615.19 EDW
100			_qLionel D. Edwards
222			_aPrinciples and Practice of Pharmaceutical Medicine. _b¼ activities administration adverse drug reactions adverse events advertising analysis application approval assessment audit biological CHMP Clin clinical research clinical studies clinical trials compliance conduct costs countries CRFs CRO data mining database disease documents dose drug development DTC advertising effect efficacy EMEA ethics committee European evaluation example FDA GCP groups Guidance guidelines Health healthcare human important increased informed consent interactions investigational product investigator involved issues labeling manufacturing measures medicinal products ment metabolism mithridatium monitoring NDA orphan drug OTC outcomes patients pediatric phar pharma pharmaceutical companies pharmaceutical industry Pharmaceutical Medicine pharmaceutical physician pharmacoeconomic pharmacokinetic pharmacology pharmacovigilance phase placebo plasma population potential prescribed prescription procedures protocol regulations regulatory authorities reports response risk safety sample scientific specific sponsor standards statistical subjects thalidomide therapeutic therapy tion toxicity treatment United Kingdom usually
240			_aPrinciples and Practice of Pharmaceutical Medicine.
245			_aPrinciples and Practice of Pharmaceutical Medicine.
246			_aPrinciples and Practice of Pharmaceutical Medicine.
247			_aPrinciples and Practice of Pharmaceutical Medicine.
250			_a2nd. Edition
260			_a111 River Street, Hoboken, NJ 07030, USA | _bJohn Wiley & Sons Inc | _c2007.
300			_a780 Pages
300			_aIncludes bibliographical references and index.
520			_aThe long awaited second edition of Principles and Practice of Pharmaceutical Medicine provides an invaluable guide to all areas of drug development and medical aspects of marketing. The title has been extensively revised and expanded to include the latest regulatory and scientific developments. New chapters include: European Regulations Ethics of Pharmaceutical Medicine Licensing and Due Diligence Pharmacogenomics Encompassing the entire spectrum of pharmaceutical medicine, it is the most up-to-date international guide currently available. Review of the first edition: “This book was a joy to read and a joy to review. All pharmaceutical physicians should have a copy on their bookshelves, all pharmaceutical companies should have copies in their libraries.” —BRITISH ASSOCIATION OF PHARMACEUTICAL PHYSICIANS
600			_xMedical / General, Medical / Pharmacology, Business & Economics / Industries / Pharmaceutical & Biotechnology, Medical / Pharmacy, Drug development, Drugs -- Research, Pharmacology.
700			_q Peter D. Stonier
700			_qAndrew J. Fletcher
700			_qAnthony W. Fox
942			_2ddc _cEB _n0
999			_c29799 _d29799